Life Sciences
Overview
Investment Banking
for Life Sciences
Cardiff Advisory delivers strategic and financial advisory services that accelerate growth, partnerships, and exits for life sciences innovators.
Our expertise spans biotechnology, diagnostics, medical devices, and digital health—bridging scientific discovery with market success.
Life Sciences Clients Advised
Provided strategic and valuation guidance that led to growth, funding, or M&A within the past 24 months.
Combined Transaction Value
Representing successful capital raises, partnerships, and acquisitions across the life sciences ecosystem.
Overview
Investment Banking
for Life Sciences
Cardiff Advisory delivers strategic and financial advisory services that accelerate growth, partnerships, and exits for life sciences innovators.
Our expertise spans biotechnology, diagnostics, medical devices, and digital health—bridging scientific discovery with market success.
Life Sciences Clients Advised
Provided strategic and valuation guidance that led to growth, funding, or M&A within the past 24 months.
Combined Transaction Value
Representing successful capital raises, partnerships, and acquisitions across the life sciences ecosystem.
Services
1. M&A and Strategic Advisory
Comprehensive sell- and buy-side support for biopharma and medtech companies seeking growth, partnerships, or exits. We deliver customized transaction strategies, identify ideal partners, and negotiate outcomes that maximize shareholder value.
4. Capital Formation Advisory
Guidance on structuring private placements, venture rounds, and strategic investments. We connect innovators with aligned investors across healthcare and technology.
2. Licensing and Partnering Strategy
We craft strategic licensing frameworks and co-development agreements that align innovation with market access, leveraging Cardiff’s relationships across pharma, biotech, and CDMOs.
5. Fractional CXO Services
Interim corporate development or financial leadership from seasoned executives to accelerate transactions, investor readiness, or strategic pivots.
3. Valuation and Financial Modeling
Independent, defensible valuations supporting transactions, IP portfolios, and 409A compliance. Our methodologies combine scientific expertise with financial rigor.
Services
1. M&A and Strategic Advisory
Comprehensive sell- and buy-side support for biopharma and medtech companies seeking growth, partnerships, or exits. We deliver customized transaction strategies, identify ideal partners, and negotiate outcomes that maximize shareholder value.
4. Capital Formation Advisory
Guidance on structuring private placements, venture rounds, and strategic investments. We connect innovators with aligned investors across healthcare and technology.
2. Licensing and Partnering Strategy
We craft strategic licensing frameworks and co-development agreements that align innovation with market access, leveraging Cardiff’s relationships across pharma, biotech, and CDMOs.
5. Fractional CXO Services
Interim corporate development or financial leadership from seasoned executives to accelerate transactions, investor readiness, or strategic pivots.
3. Valuation and Financial Modeling
Independent, defensible valuations supporting transactions, IP portfolios, and 409A compliance. Our methodologies combine scientific expertise with financial rigor.
Therapeutics
- Aesthetics / Skin Care
- Autism
- Autoimmune
- Cancer/ Oncology
- Cardiovascular
- Dermatology
- Gastroenterology
- Genomics/Genetics
- Immune-oncology
- Ophthalmology
- Neurology/Neurodegenerative/Neuromuscular
- Rare / Orphan
- Renal / Nephrology
- Reproductive
- Surgical
- Uro-GYN/OB
- Women’s Health
Therapeutics
- Aesthetics / Skin Care
- Autism
- Autoimmune
- Cancer/ Oncology
- Cardiovascular
- Dermatology
- Gastroenterology
- Genomics/Genetics
- Immune-oncology
- Ophthalmology
- Neurology/Neurodegenerative/Neuromuscular
- Rare / Orphan
- Renal / Nephrology
- Reproductive
- Surgical
- Uro-GYN/OB
- Women’s Health
Technologies
- Small Molecule Chemistry
- Brand and Generic
- Medical Device
- OTC / Nutraceuticals /Skin care
- Diagnostics
- Personalized Medicine
- Digital Health
- SaaS
- Life Science Tools / Cells / Reagents /Assays
- Genomic/ Data Sciences
- CDMO/ CRO Services
- Microscopy / Imaging
- AI/ ML- enabled tech
Technologies
- Small Molecule Chemistry
- Brand and Generic
- Medical Device
- OTC / Nutraceuticals /Skin care
- Diagnostics
- Personalized Medicine
- Digital Health
- SaaS
- Life Science Tools / Cells / Reagents /Assays
- Genomic/ Data Sciences
- CDMO/ CRO Services
- Microscopy / Imaging
- AI/ ML- enabled tech
Medical Device
- 510k
- De Novo
- PMA
Medical Device
- 510k
- De Novo
- PMA
Biologies
- Biologics
- Proteins
- Neurotoxins
- Collagen / Fillers
- Vaccines
- Antibodies
- Cell therapies
- Stem Cell
- Bacteriophage
- mRNA
Biologies
- Biologics
- Proteins
- Neurotoxins
- Collagen / Fillers
- Vaccines
- Antibodies
- Cell therapies
- Stem Cell
- Bacteriophage
- mRNA
Case Studies
GenomicDx
Advised on a $45M Series B capital raise in precision oncology diagnostics.
NeuroVive
Supported a $120M cross-border M&A transaction in neurodegenerative therapeutics.
DermAesthetix
Strategic advisory for a $75M
sale to a global aesthetics
company
BioPhage Tx
Structured a $25M
co-development agreement in bacteriophage therapy.
Ophthalis
Managed a $60M acquisition of an ophthalmology biotech by a mid-cap pharma.
CardiONX
Guided a $40M joint venture in cardiovascular digital therapeutics
CellVax Bio
Supported a $15M
Series A financing in next-gen
cell therapy.
NeuroHeal
Partnered in a $50M merger between two neurology platform companies.
DermLab
Led valuation and strategic advisory for a $10M venture equity investment.
Case Studies
GenomicDx
Advised on a $45M Series B capital raise in precision oncology diagnostics.
NeuroVive
Supported a $120M cross-border M&A transaction in neurodegenerative therapeutics.
DermAesthetix
Strategic advisory for a $75M
sale to a global aesthetics
company
BioPhage Tx
Structured a $25M
co-development agreement in bacteriophage therapy.
Ophthalis
Managed a $60M acquisition of an ophthalmology biotech by a mid-cap pharma.
CardiONX
Guided a $40M joint venture in cardiovascular digital therapeutics
CellVax Bio
Supported a $15M
Series A financing in next-gen
cell therapy.
NeuroHeal
Partnered in a $50M merger between two neurology platform companies.
DermLab
Led valuation and strategic advisory for a $10M venture equity investment.
Partners
BA Securities, LLC
Oppenheimer & Co.
SVB Leerink Partners
Takenaka Partners
Deloitte
Procopio LLP
Partners
BA Securities, LLC
Oppenheimer & Co.
SVB Leerink Partners
Takenaka Partners
Deloitte
Procopio LLP
Insights
Success in life sciences depends on pairing breakthrough innovation with strategic timing and the right capital partner.
Our insight: the most successful exits emerge when science, valuation, and strategy are aligned early in the company lifecycle.
Insights
Success in life sciences depends on pairing breakthrough innovation with strategic timing and the right capital partner.
Our insight: the most successful exits emerge when science, valuation, and strategy are aligned early in the company lifecycle.
Connect
Let’s discuss how Cardiff Advisory can help accelerate your life sciences strategy.
Whether you’re raising capital, seeking partners, or exploring an exit, our senior team brings the relationships and experience to help you achieve optimal outcomes.
Connect
Let’s discuss how Cardiff Advisory can help accelerate your life sciences strategy.
Whether you’re raising capital, seeking partners, or exploring an exit, our senior team brings the relationships and experience to help you achieve optimal outcomes.